Extended Blood Group Antigen Profile Testing
We perform automated DNA-based typing for both donor and patient samples for blood centers, clinics, and hospitals across the country. Our extensive testing goes beyond serological methods, identifying antigens that are otherwise inaccessible, uncovering rare antigen combinations, detecting weak antigens, and identifying rare blood units.
We utilize the FDA-licensed, DNA-based multiplex PCR assay coupled with a robust beadchip microarray for extended red cell typing. This method allows us to analyze donor and patient samples efficiently, correlating well with serology results. The test, which processes up to 96 samples at once, analyzes 11 clinically significant blood groups, predicting 35 red blood cell antigens without requiring confirmatory serology testing.
PreciseMatch® Blood Products
NYBCe specializes in providing PreciseMatch® blood products nationwide, helping to reduce complications, optimize transfusion compatibility, and enhance the safety of transfusion practices. These antigen-matched blood products are tailored for patients who require precise compatibility with common clinically significant antigens.
PreciseMatch® Blood Products Benefit:
- Patients for whom compatibility cannot be demonstrated by routine testing including
- Patients with warm autoantibodies
- Patients receiving monoclonal antibody therapies that interfere in testing.
- Patients who face chronic transfusions and are at risk for alloimmunization complications.
- Patients who experience hemolytic reactions or reduced red cell survival after transfusions.
- Patients with hemoglobinopathies, congenital anemias, bone marrow failure syndromes, or malignancies.
When Is HEA Genotyping Useful?
HEA genotyping is particularly valuable for patients in whom traditional serologic testing may be challenging or insufficient, including:
- Patients with multiple or complex alloantibodies, supporting selection of antigen negative red blood cell units
- Patients who are chronically transfused, such as patients with sickle cell disease, thalassemia, and oncology/hematology patients
- Patients who have been recently transfused, as molecular methods are not affected by the presence of donor cells in a sample
- Patients with a positive DAT or autoantibodies, when serologic phenotyping is unreliable
- Pre-transfusion planning, reducing the risk of future alloimmunization
- High-throughput donor screening for blood collection facilities, growing and supporting maintenance of antigen negative inventory